The Emami Story: How a Dream Born in Kolkata Became a Global FMCG Legacy

Date:

Share post:

During 1970’s in the bustling street of Kolkata, two friends walked away from stable corporate jobs with little more than a dream and a tiny office, with the aim of building a company and to challenge the established multinational giants that dominated the Indian personal care market. This was the birth of of Emami. Co-founded by RS Agarwal and RS Goenka, Emami is currently India’s leading FMCG company with turnover of Rs. 3809Cr in the financial year 2025, 550+products, 20+ brands, 3200+ employees,70+ global market.

Emami flourished by spotting the gaps in the market, identifying the needs people, which they didn’t even know they had. Their first major breakthrough came with “BoroPlus”. An innovation of blending antiseptic properties with skin moisturization, they created a household staple that felt like a mother’s touch in a tube. India’s No 1 Antiseptic Cream the trusted brand that has become a household name. However, their true stroke of genius was “Fair and Handsome” now rebranded as “Smart and Handsome” cream.  

Emami doesn’t just focus on chemical formulations; it applies emotional intelligence. Whether it’s the cooling relief of Navratna Oil , Dermi Cool powder during the scorching Indian summer or the wellness promise of “Zandu Balm”, and also the secret to your beautiful lengthy hair “Kesh King”, “7 oils in one”, Emami advertisements focuses on making the product too generic, making it easily acceptable in common household.

“Navratna Arctic Blossom Talc” recognized as a Nielsen Breakthrough Innovation Award (BIR) Winner 2025, a rare and prestigious distinction that celebrates most impactful innovation backed by sustained in-market performance. Adding one more to their glory, “Zandu Chyavanprash Jaggery” has been awarded in TWO categories by Exchange4media at their 6th edition of e4m Health & Wellness Marketing Awards – 2025:
• Best Preventive Health Care Campaign – Silver
• Best Seasonal Topical Wellness Campaign-Bronze On a consolidated basis from the Q3FY26 reports, net sales recorded double-digit growth of 11%, with revenues reaching ₹1,152 crore, representing a year-on-year growth of 10% during the quarter. The domestic business delivered growth of 11%, driven by robust volume growth of 9%. On 9th May 2026,  the Sensex share price of Emami was trading at Rs. 456.95.

Emami’s International Business Division has expanded its footprint across multiple continents to consumers worldwide. Mr. Harsh Vardhan Agarwal, the Vice Chairman & Managing Director of Emami Limited has been recognised as the Honorary Consul of Austria in Kolkata, in the year 2026 by the Austrian Embassy, New Delhi. 

Emami Limited has received an appreciation letter from the United States Pharmacopeia (USP) for developing the monograph on Shatavari (Asparagus racemosus) roots, powder, and extract. USP is a globally recognized, non-profit scientific organization that establishes official quality standards for medicines, dietary supplements, and healthcare products. This reflects Emami’s unwavering commitment t to scientific excellence, robust quality standards, and global regulatory harmonisation in the field of traditional and herbal medicines.

By Pragna Biswas

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Dabur India Plant Under US FDA Scanner Over Contamination Concerns

The United States Food and Drug Administration (US FDA) has flagged serious concerns at Dabur India's manufacturing facility...

FDA Approves Wockhardt’s Novel Antibiotic ZAYNICH™️ for cUTI

Wockhardt Limited  announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepimeand zidebactam), a novel intravenous antibiotic...

Relief for Patients: NPPA Fixes Ceiling Prices for 30 Essential Medicines

The National Pharmaceutical Pricing Authority (NPPA) has notified ceiling prices for 30 essential fixed-dose combination medicines under the...

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

The U.S. Food and Drug Administration (FDA) issued a new draft guidance aimed at reducing unnecessary animal testing...